FDA Approves Ziftomenib for Relapsed or Refractory Acute Myeloid Leukaemia with a NPM1 Mutation By Ogkologos - November 20, 2025 345 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the KO-MEN-001 study Source RELATED ARTICLESMORE FROM AUTHOR FDA Approves Allogeneic Regulatory T Cell-Based Immunotherapy with HSPC and T Cells-vldq for Use in Matched Donor HSCT for Adult Patients with Haematologic Malignancies Combination of mFOLFOX6/Bevacizumab Plus Atezolizumab Prolongs PFS Compared with Atezolizumab in First-Line Treatment of dMMR/MSI-H mCRC Use of YEARS Algorithm, D-dimer Levels, and Performing Risk-Dependent CT Pulmonary Angiography is Safe in Patients with Cancer and Suspected Pulmonary Embolism MOST POPULAR How Fatty Liver Disease Helps Cancer Thrive in the Liver July 6, 2023 Utility of Genomic Profiling of cfDNA to Inform Clinical Care for... September 28, 2022 Combination of Azacitidine and Venetoclax in Previously Untreated AML August 18, 2020 ESMO Clinical Practice Guideline Express Update on the adoption of physical... January 27, 2026 Load more HOT NEWS Genetic Cancer Screenings in Younger Women May Be Cost-Effective and Lead... T-DM1 Approval Expanded to Include Some Women with Early-Stage HER2-Positive Breast... Cancer Research UK’s Race for Life celebrates its 30th year by... New ESMO President 2029-2030 Elected
